Home/Pipeline/Luvadaxistat (NBI-1065844)

Luvadaxistat (NBI-1065844)

Negative Symptoms of Schizophrenia

Phase IIActive (INTERCEPT)NCT05544166

Key Facts

Indication
Negative Symptoms of Schizophrenia
Phase
Phase II
Status
Active (INTERCEPT)
Company

About Neurocrine Biosciences

Neurocrine Biosciences has successfully transitioned from a discovery-focused entity to a fully integrated commercial leader in neuroscience. Its mission is to relieve suffering through brave science, exemplified by the blockbuster success of INGREZZA for tardive dyskinesia and a growing portfolio in movement disorders and endocrinology. The company's strategy leverages deep neurobiological expertise to advance a diversified pipeline, pursue strategic collaborations, and expand the labels of its commercial assets to drive sustainable growth.

View full company profile

Other Negative Symptoms of Schizophrenia Drugs

DrugCompanyPhase
CT-155Click TherapeuticsPhase 3